Aegle Therapeutics

Thank you debra of America for hosting us last week for a webinar. The recording of "Unlocking Potential: Aegle's New Clinical Trial for RDEB Wounds" is now available online: https://lnkd.in/g7WmiNXk

Now Enrolling! Aegle's Phase 1/2a clinical trial of AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. To learn more about the Aegle DEB Clinical Study, please see our Informational Brochure or visit ClinicalTrials.gov. Informational Brochure: https://lnkd.in/eUJjyVGW

Aegle Therapeutics CEO Shelley A. Hartman will co-chair the Exosome Characterization & Analytical Development Summit in Boston this week. We hope to see you there! 50+ EV Analytical Development leaders will converge to delve into the cutting-edge realm of exosome characterization and analytical approaches - from assay to data requirements. https://ter.li/iog378

We’re thrilled to announce positive data for the first patient in a Phase 1/2a clinical trial dosed with AGLE-102, a novel extracellular vesicle therapy. Learn more: https://lnkd.in/e-du-FBS

Aegle Therapeutics CEO Shelley A. Hartman is kicking off the New Year with a presentation at #BiotechShowcase on Monday, January 8th at 10:15am (Franciscan A-Ballroom Level). We look forward to connecting with many of you at the conference!

Aegle Therapeutics CEO Shelley A. Hartman joined BioWorld and other biopharma executives to discuss 2023 challenges and opportunities for the year ahead. Check out the insightful podcast! https://lnkd.in/eg48P8yz

Aegle Therapeutics is excited to present at #BiotechShowcase on January 8th! We hope to see you in San Francisco for the healthcare conference.

Today is #GivingTuesday, a global day of generosity. Aegle Therapeutics is a proud supporter of debra of America and its mission to improve the quality of life for all people living with #EpidermolysisBullosa. Thank you debra of America for spotlighting Willistine Lenon, VP of Clinical Operations at Aegle Therapeutics and her passion for #EB advocacy. 

Congratulations to debra of America on a successful Annual Benefit! It was an amazing evening to celebrate progress in #epidermolysisbullosa research and to honor the #EB community.

While today is the last day of #EBAwarenessWeek, Aegle remains committed to increasing awareness of #EpidermolysisBullosa (EB) and working towards a cure for this debilitating rare connective tissue disorder. Learn more about EB and take action at //debra.org/ebweek #EBweek #WeFightEB